CLINICAL MANAGEMENT OF METABOLIC PROBLEMS IN PATIENTS WITH SCHIZOPHRENIA:SW

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 精神分裂症患者已经被证明有更多的代谢异常，这是心血管风险的指标，比他们匹配的对照。 一些用于治疗精神分裂症的药物与这些代谢异常有关。 精神分裂症患者和心血管疾病代谢危险因素的最佳治疗策略尚未确定。 这项研究旨在了解转换为一种新的药物的风险和好处，这种药物产生代谢副作用的可能性较低，而不是继续使用一种高代谢副作用的药物。 易产生代谢副作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients with schizophrenia have been shown to have more metabolic abnormalities, which are indicators for cardiovascular risk, than their matched controls. Some of the medications used to treat schizophrenia are associated with these metabolic abnormalities. The best treatment strategies for patients with schizophrenia and metabolic risk factors for cardiovascular disease have not yet been established. This study seeks to understand the risks and benefits of switching to a new medication with a low liability of producing metabolic side effects versus staying on a medication with a high liability of producing metabolic side effects.